The common serious adverse events included abdominal pain 8.2% (5/61), neutropenia 6.6% (4/61), thrombocytopenia 4.9% (3/61), ALT increase 3.3% (2/61), and AST increase 3.3% (2/61). This evidence concerns the gene GPT and Thrombocytopenia.